Ann: MAYNE PHARMA provides FDA update on generic NUVARING, page-50

Its not just us retail shareholders especially long time holders who have every reason to get this company back on track , on our own we've been in a helpless position and you're right Biggsy there's a number of us "stuck" living in hope but now not so much , Mithra heavily invested with plenty to lose if this company remains "ongoing disaster led by incompetence". We're not in the same position as we were . Mithra now a major shareholder in Mayne plenty of skin in the game they're banking on E4 success as much as we are , can't see Mithra being treated as wood ducks like the way Mayne's been able to treat its retail shareholders after all they own the product of course they want to look after it plus expect some growth in their massive share holding . Fact they've appointed their representative Dr Myers who specializes in business and marketing strategy as a director on Maynes board Mthra knows our management not up to the task . Dead wood gone hopefully .